Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Etelcalcetide

FDA-approved product (solution, intravenous), marketed as Parsabiv.

Registered studies
23
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Etelcalcetide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Parathyroid disease
  • Secondary hyperparathyroidism

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other anti-parathyroid agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

23registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Etelcalcetide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Etelcalcetide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

    NCT01785875 · start 2013-07-31

    Registered record
    Registry ID
    NCT01785875
    Conditions
    Hyperparathyroidism, Secondary
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07-31
    Completion
    2015-07-01
    Enrolment
    891

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperparathyroidism, Secondary
    InterventionEtelcalcetide
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

    NCT01785849 · start 2013-03-12

    Registered record
    Registry ID
    NCT01785849
    Conditions
    Hyperparathyroidism, Secondary
    Interventions
    Etelcalcetide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03-12
    Completion
    2014-06-12
    Enrolment
    508

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperparathyroidism, Secondary
    InterventionEtelcalcetide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

    NCT01788046 · start 2013-03-12

    Registered record
    Registry ID
    NCT01788046
    Conditions
    Hyperparathyroidism, Secondary
    Interventions
    Etelcalcetide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03-12
    Completion
    2014-05-09
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperparathyroidism, Secondary
    InterventionEtelcalcetide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism

    NCT01576146 · start 2012-03

    Registered record
    Registry ID
    NCT01576146
    Conditions
    Secondary Hyperparathyroidism
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-03
    Completion
    2014-05-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism
    InterventionEtelcalcetide
    PhasePhase 2
    Registry statusTerminated

  • Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder

    NCT01414114 · start 2011-12-05

    Registered record
    Registry ID
    NCT01414114
    Conditions
    Secondary Hyperparathyroidism
    Interventions
    Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-12-05
    Completion
    2012-05-21
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism
    InterventionEtelcalcetide
    PhasePhase 2
    Registry statusCompleted

  • Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

    NCT01254565 · start 2011-02-20

    Registered record
    Registry ID
    NCT01254565
    Conditions
    Secondary Hyperparathyroidism
    Interventions
    Etelcalcetide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-02-20
    Completion
    2011-08-24
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Hyperparathyroidism
    InterventionEtelcalcetide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

    NCT01134562 · start 2010-09-07

    Registered record
    Registry ID
    NCT01134562
    Conditions
    Hyperparathyroidism, Secondary
    Interventions
    Placebo; Etelcalcetide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-09-07
    Completion
    2011-04-02
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperparathyroidism, Secondary
    InterventionPlacebo; Etelcalcetide
    PhasePhase 1
    Registry statusCompleted

  • Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers

    NCT01134549 · start 2010-06-09

    Registered record
    Registry ID
    NCT01134549
    Conditions
    Hyperparathyroidism, Secondary
    Interventions
    Etelcalcetide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-06-09
    Completion
    2010-07-31
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperparathyroidism, Secondary
    InterventionEtelcalcetide; Placebo
    PhasePhase 1
    Registry statusCompleted